Trial reportAnnals of oncology : official journal of the European Society for Medical Oncology2012
A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
Trial report in Annals of oncology : official journal of the European Society for Medical Oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00628628 (Phase 2 Study of Rasburicase Administered by Two Different Schedules), which is not on this map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 2 Study of Rasburicase Administered by Two Different Schedules (Fixed Dosing vs. As Needed Dosing) in Patients at High Risk or Potential Risk for Tumor Lysis Syndrome
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 92 citations in OpenAlex.
- Guidelines for treatment of renal injury during cancer chemotherapy 2016.Clinical and experimental nephrology · 2018Guideline
- Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.The Cochrane database of systematic reviews · 2017Pooled it
- Designer probiotic-based living drugs for uric acid homeostasis control in hyperuricemic mice and rats.Cell reports. Medicine · 2025Article
- Tumour lysis syndrome.Nature reviews. Disease primers · 2024Review
- Synthetically mannosylated antigens induce antigen-specific humoral tolerance and reduce anti-drug antibody responses to immunogenic biologics.Cell reports. Medicine · 2024Article
- Tumor Lysis Syndrome: An Endless Challenge in Onco-Nephrology.Biomedicines · 2022Review
- Fixed-Dose Recombinant Urate Oxidase in the Treatment of Paediatric Tumour Lysis Syndrome: A Regional Cancer Centre Experience.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Evaluation of the safety and efficacy of low-dose rasburicase in critically ill children with haematological malignancies.International journal of clinical pharmacy · 2020Article
- Acute kidney injury in the patient with cancer.Kidney research and clinical practice · 2019Review
- Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2018Article
- Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.The oncologist · 2017Review
- Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase.OncoTargets and therapy · 2017Review
- Kidney diseases associated with haematological cancers.Nature reviews. Nephrology · 2015Review
- Low-dose rasburicase in hematologic malignancies.Indian journal of pediatrics · 2015Article
- Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experience.Oncology letters · 2015Article
- Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy.Core evidence · 2015Review
- Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndrome.Oncology letters · 2014Article
- PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.Pharmacogenetics and genomics · 2014Review
- Tumor lysis syndrome: new challenges and recent advances.Advances in chronic kidney disease · 2014Review
- PharmGKB summary: methylene blue pathway.Pharmacogenetics and genomics · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundTumor lysis syndrome (TLS) is a life-threatening disorder characterized by hyperuricemia and metabolic derangements. The efficacy of rasburicase, administered daily for 5 days, has been well established. However, the optimal duration of therapy is unknown in adults. PATIENTS AND
methodsWe evaluated the efficacy of rasburicase (0.15 mg/kg) administered as single dose followed by as needed dosing (maximum five doses) versus daily dosing for 5 days in adult patients at risk for TLS.
resultsEighty of the 82 patients enrolled received rasburicase; 40 high risk [median uric acid (UA) 8.5 mg/dl; range, 1.5-19.7] and 40 potential risk (UA = 5.6 mg/dl; range, 2.4-7.4). Seventy-nine patients (99%) experienced normalization in their UA within 4 h after the first dose; 84% to an undetectable level (<0.7 mg/dl). Thirty-nine of 40 (98%) patients in the daily-dose arm and 34 of 40 (85%) patients in single-dose arm showed sustained UA response. Six high-risk patients within the single-dose arm required second dose for UA >7.5 mg/dl. Rasburicase was well tolerated; one patient with glucose-6-phosphate dehydrogenase deficiency developed methemoglobinemia and hemolysis.
conclusionsRasburicase is highly effective for prevention and management of hyperuricemia in adults at risk for TLS. Single-dose rasburicase was effective in most patients; only a subset of high-risk patients required a second dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.